Century Therapeutics (IPSC) Total Current Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has reported Total Current Liabilities for 7 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 6.46% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (down 6.46% YoY), while the FY2025 annual figure was $20.2 million, down 84.42% from the prior year.
• Total Current Liabilities slipped to $13.6 million in Q1 2026 per IPSC's latest filing, from $20.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $129.8 million in Q4 2024 and bottomed at $13.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $26.8 million across 5 years, with a median of $20.2 million in 2025.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 627.23% — and 2025, when it tumbled 84.42%.
• Century Therapeutics' Total Current Liabilities stood at $29.8 million in 2022, then slumped by 40.15% to $17.8 million in 2023, then jumped by 627.23% to $129.8 million in 2024, then sank by 84.42% to $20.2 million in 2025, then sank by 32.93% to $13.6 million in 2026.
• Business Quant data shows IPSC's Total Current Liabilities at $13.6 million in Q1 2026, $20.2 million in Q4 2025, and $22.0 million in Q3 2025.